Angelini Ventures and Apollo Health Ventures led a $39m Series A extension round in Therini Bio.

Angelini Ventures and Apollo Health Ventures led a $39m Series A extension round in Therini Bio, a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction, with participation from SV Health Investors’ Biotech Fund, Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures and Foundation for a Better World. ”We are proud to support Therini Bio’s mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active CNS investor, we are excited about Therini’s first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer’s and DME," Thomas Thestrup, Angelini Ventures Senior Principal.